New cocktail of cancer drugs shows promise in early leukemia trial
NCT ID NCT04872790
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when combined with other drugs like dasatinib and prednisone. The main goal is to check for side effects, but researchers will also look at how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- venetoclax (a BCL-2 inhibitor) combined with dasatinib, prednisone, rituximab, and blinatumomab
- What this could lead to
- If successful, this could lead to a more effective treatment option for Philadelphia chromosome-positive acute lymphoblastic leukemia, potentially improving remission rates.
- What could go wrong
- This is a very early (Phase 1) trial with only 20 participants, focused on finding the right dose and checking safety. It is too small to prove effectiveness, and side effects from the drug combination are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA WITH T(9;22)(Q34.1;Q11.2); BCR-ABL1 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells outsmart resistant blood cancers?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests
- Can a Chemo-Antibody combo beat a tough leukemia?
- Could a simple drug tame the dangerous side effects of CAR-T cancer therapy?
- Epigenetic drugs aim to stop cancer return after transplant in kids
- New drug cocktail aims to improve remission in older leukemia patients